Cyprium’s CUTX-101 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Menkes Disease

 Cyprium’s CUTX-101 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Menkes Disease

Cyprium’s CUTX-101 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Menkes Disease

Shots:

  • The US FDA has granted BTD to CUTX-101 for the potential treatment of Menkes disease
  • The FDA has previously ODD, FTD and RPDD to CUTX-101 for the treatment of Menkes disease. Additionally, the EMA has previously granted ODD to CUTX-101
  • The rolling submission of NDA to the US FDA for CUTX-101 is expected to be initiated in Q1’21 and to be completed by the end of the Q2’21

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Cyprium

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post